비수술 후 통증 관리 : 시장 인사이트, 역학 및 시장 예측(2036년)

Non-Postoperative Pain Management Insights and Trends

• According to DelveInsight's analysis, moderate-to-severe non-postoperative pain management market size was found to be ~USD 3,400 million in the leading markets (the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan) in 2025.
• Non-postoperative acute pain management follows a multimodal approach, integrating pharmacological therapies (NSAIDs, acetaminophen, opioids, corticosteroids, and adjuncts) with non-pharmacological interventions such as physical therapy, cognitive-behavioral therapy (CBT), acupuncture, and TENS to enhance outcomes and minimize reliance on single modalities.
• Multimodal treatment remains critical in non-postoperative settings, as combining different mechanisms of action provides additive or synergistic pain relief while reducing the risk of adverse effects associated with high-dose monotherapy.
• There is a growing shift toward non-opioid pain management strategies, driven by concerns over opioid overuse, with studies indicating that a significant proportion of prescribed opioids remain unused and are associated with notable side effects.
• NSAIDs continue to play a central role in acute pain management; however, their use is associated with gastrointestinal, renal, and cardiovascular risks, necessitating careful patient selection and monitoring.
• Psychosocial and behavioral interventions, including meditation, distraction techniques, and breathing exercises, are increasingly recognized as essential components of non-postoperative pain management, although they remain underutilized compared to pharmacological options.
• There is a significant unmet need for rapid-onset, non-opioid therapies in specific acute pain conditions such as migraine, with clinicians highlighting the limitations of existing treatment options in achieving timely and effective relief.
• The non-postoperative acute pain market is witnessing innovation through novel formulations and drug delivery approaches, including self-administered and fast-acting therapies designed to improve patient convenience and adherence.
• Key players in the non-postoperative acute pain space include companies such as Teikoku Pharma, Cessatech, and Vaneltix Pharma, reflecting growing industry focus on non-opioid and patient-centric treatment approaches.
• Overall, the non-postoperative acute pain market is expected to evolve significantly, driven by increasing demand for safer alternatives, rising disease burden (e.g., migraine), and continued advancements in targeted therapies and delivery systems.

Non-Postoperative Pain Management Market Size and Forecast in the 7MM

• 2025 Non-Postoperative Moderate-to-severe Acute Pain Market Size: ~USD 3,400 million
• Moderate-to-severe Acute management Growth Rate (2026-2036): ~10% CAGR

DelveInsight's 'Non-Postoperative pain management - Market Insights, Epidemiology and Market Forecast - 2036' report delivers an in-depth understanding of the Non-Postoperative pain management, historical and forecasted epidemiology, as well as the Non-Postoperative pain management market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

The Non-Postoperative pain management market report delivers a comprehensive analysis of the current treatment landscape, including standards of care, clinical practices, and evolving therapeutic algorithms. It evaluates, Non-Postoperative pain management patient burden trends, revenue & market share dynamics, peak patient share & therapy uptake analysis, and provides an in-depth market size assessment, and growth rate projections (Historical & Forecast 2022-2036) across global regions. The report highlights key unmet medical needs in Postoperative pain management and maps the competitive and clinical landscape to uncover high-value opportunities, providing a clear outlook on future market growth potential.

Key Factors Driving the Non-Postoperative Pain Management Market

• Opioid Safety Concerns and Underutilization Driving Non-Opioid Shift

Real-world evidence shows that 42-71% of prescribed opioids remain unused, while 16-29% of patients experience adverse effects, accelerating the transition toward non-opioid and opioid-sparing treatment strategies.

• High and Recurring Burden of Acute Pain Conditions

Conditions such as migraine, musculoskeletal injuries, and episodic pain disorders contribute to a large, recurrent patient population, driving sustained demand for effective and rapid pain relief options.

• Unmet Need for Rapid-Acting and Reliable Therapies

Existing treatments often demonstrate delayed onset and variable efficacy, particularly in migraine, highlighting the need for fast-acting, patient-convenient therapies with consistent clinical response.

Non-Postoperative Pain Management Understanding and Treatment Algorithm

Non-Postoperative Pain Overview and Diagnosis

Effective management of non-postoperative acute pain is critical to reduce patient suffering, maintain function, and prevent progression to chronic pain. Acute pain commonly arises from trauma, infections, musculoskeletal injuries, burns, dental conditions, or medical illness, and is mediated through nociceptive pathways involving tissue damage and inflammatory mediators. However, pain perception is highly subjective and varies significantly across individuals due to differences in nerve signaling, psychological factors, and prior pain experiences. Inadequately controlled acute pain can lead to physiological stress responses, sleep disturbance, impaired recovery, and in some cases transition into chronic pain, particularly when associated with severe or prolonged nociceptive stimulation.

Diagnosis and assessment of non-postoperative acute pain is primarily clinical and depends on detailed patient history, including onset, duration, intensity, and location of pain, along with evaluation of possible underlying causes such as injury, infection, or inflammation. Pain is objectively quantified using validated assessment tools such as the Visual Analog Scale (VAS), Numeric Rating Scale (NRS), Verbal Rating Scale (VRS), and Wong-Baker Faces Scale, while multidimensional tools like the McGill Pain Questionnaire (MPQ) and Brief Pain Inventory (BPI) help evaluate broader functional and psychological impact.

When clinically indicated, supportive investigations may be used to identify underlying pathology, including:

• Blood investigations (to assess infection or inflammation)
• X-rays (for fractures or structural injury)
• CT or MRI scans (for soft tissue, nerve, or internal injury assessment)
• Ultrasound imaging (for organ or soft tissue evaluation)
• Nerve conduction studies (for suspected neuropathic involvement)
• Dye-based imaging studies (for specific diagnostic clarification)

Current Non-Postoperative Pain Management Treatment Landscape

Non-postoperative pain management refers to the treatment of acute pain from non-surgical causes such as trauma, infection, musculoskeletal injury, burns, or dental conditions. It follows a stepwise WHO pain ladder approach, starting with non-pharmacological measures and non-opioid analgesics, escalating to weak or strong opioids for severe pain, with adjunct therapies as needed. A multimodal analgesia strategy is widely used to improve pain control while reducing opioid dependence.

Management includes non-pharmacological interventions like cold application, compression, elevation, immobilization, and rehabilitation therapies, along with pharmacological options such as NSAIDs, acetaminophen, topical agents, anticonvulsants, ketamine, and short-course opioids. The goal is effective pain relief, functional improvement, and prevention of chronic pain progression.

Non-Postoperative Pain Management Unmet Needs

The section "unmet needs of Non-Postoperative Pain Management" outlines the critical gaps between the current state of patient care, diagnosis, and the ideal & effective management of the disease. It highlights the obstacles experienced by patients, clinicians, and researchers and identifies potential solutions for future progress.

1. Awareness among clinicians regarding multimodal pain management is lagging behind

2. Challenges in migraine pain management

3. Diagnostic gaps in postoperative pain and acute pain

4. Need for procedure-specific guidelines and research

5. Gaps in implementation of pain management guidelines,and others.....

Non-Postoperative Pain Management Epidemiology

Key Findings from Non-Postoperative Pain Management Epidemiological Analysis and Forecast

• According to DelveInsight's estimates, in 2025, the total number of incident cases of Moderate-to-severe Non- Postoperative Pain in the 7MM were ~91 million.
• Across the 7MM, non-postoperative pain burden is strongly driven by a high volume of injury- and trauma-related cases, with the US alone reporting approximately 40 million injury-related emergency department visits (2020), accounting for about 12% of total population exposure.
• Trauma-related long-term pain remains highly prevalent, with evidence showing that ~62.7% of injured patients report persistent pain up to 12 months post-injury, highlighting a major source of chronic non-postoperative pain burden.
• Migraine and severe headache disorders, a major contributor to non-postoperative pain, affect a substantial proportion of the population, with prevalence ranging from ~6-16% across key markets (e.g., US ~16%) with a large proportion remaining undiagnosed or undertreated.
• In addition to injury and headache disorders, musculoskeletal and general pain conditions represent a major outpatient burden, with injury prevalence reported at ~10-11% of populations in European countries reinforcing the consistent high demand for non-postoperative acute pain management across healthcare systems.

Non-Postoperative Pain Management Drug Analysis & Competitive Landscape

The Postoperative Pain Management drug chapter provides a detailed, market-focused review of approved therapies and the emerging pipeline across Phase I-III clinical trials. It covers mechanism of action, clinical trial data, regulatory approvals, patents, collaborations, strategic partnerships upcoming Key catalyst for each therapy, along with their advantages, limitations, and recent developments. This section offers critical insights into the Non-Postoperative Pain Management treatment landscape, supporting market assessment, competitive analysis, and growth forecasting for the Non-Postoperative Pain Management therapeutics market.

Approved Therapies for Non-Postoperative Pain Management

Dihydroergotamine (ATZUMI): Satsuma Pharmaceuticals

Dihydrorgotamine (ATZUMI) is a nasal powder is the first and only DHE nasal powder indicated for the acute treatment of migraine with or without aura in adults, delivered through a convenient, portable device. It is also the first and only product to utilize the proprietary SMART (Simple MucoAdhesive Release Technology) platform, which combines advanced powder formulation with innovative device technology to enable simplified and effective intranasal delivery of dihydroergotamine.

Meloxicam and rizatriptan (SYMBRAVO): Axsome Therapeutics

Meloxicam and rizatriptan (SYMBRAVO) is a novel, oral, single-dose therapy combining meloxicam (a COX-2 preferential NSAID) and rizatriptan (a 5-HT1B/1D agonist), formulated using MoSEIC technology to enable rapid absorption while maintaining a long half-life. It is designed to provide fast, sustained pain relief through a dual mechanism targeting both inflammatory and neurovascular pathways, with the potential to reduce symptom recurrence in acute, non-postoperative pain settings, although its exact mechanism of action is not fully established.

Non-Postoperative Pain Management Pipeline Analysis

TK-254Rx (esflurbiprofen transdermal): Teikoku Pharma

TK-254Rx is an investigational s-flurbiprofen 1.5% hydrogel patch for acute minor sport injury with a clean safety profile designed for once-daily application for up to 7 days. It uses our proprietary Hydrohesive technology and is being evaluated for use in acute strains, sprains, or contusions to reduce pain symptoms.

RizaFilm (rizatriptan): Gensco Pharma/IntelGenx

RizaFilm is a proprietary oral thin film formulation of rizatriptan benzoate. RizaFilm oral soluble film does not require a drink for swallowing and has ease of use, which facilitates rapid administration and relief from migraine symptoms. RizaFilm is an active ingredient that has been clinically proven to be effective for migraine-associated nausea, photophobia, and phonophobia. Gensco Pharma acquired global rights and IP for the only rizatriptan ODF, marketed as RizaFilm in the US and RizaFilm/RizaPort globally, in May 2025.

Non-Postoperative Pain Management Key Players, Market Leaders and Emerging Companies

• Teikoku Pharma
• Gensco Pharma
• Scilex Holding Company
• Cessatech A/S
• Allodynic Therapeutics
• Biohaven Therapeutics
• Vaneltix Pharma, and others

Non-Postoperative Pain Management Market Outlook

Non-postoperative pain is a common manifestation of acute and chronic conditions arising from non-surgical causes such as trauma, musculoskeletal injuries, infections, burns, dental pain, and neurological disorders. Despite the availability of multiple treatment options, pain remains frequently undertreated, largely due to its subjective nature and variability in patient response. Management typically involves a combination of pharmacological therapies-such as NSAIDs, acetaminophen, topical agents, anticonvulsants, ketamine, and opioids in selected cases along with non-pharmacological approaches, including cold application, compression, elevation, immobilization, physical therapy, yoga, massage, and cognitive-based interventions.

Traditionally, opioids were used for moderate-to-severe acute pain; however, concerns regarding adverse effects, dependence, and misuse have driven a shift toward multimodal analgesia (MMA). This approach combines agents with different mechanisms of action to enhance pain relief while minimizing opioid exposure. Current clinical practice emphasizes stepwise, individualized, and evidence-based pain management strategies guided by frameworks such as the WHO pain ladder, aiming to achieve tolerable pain control, improve functional outcomes, and reduce the risk of progression to chronic pain.

Recent Updates

• In March 2026, Kallyope announced it will present results from a Phase IIb dose-ranging study of its novel therapy elismetrep in an oral presentation at the 2026 American Academy of Neurology (AAN) Annual Meeting.
• In May 2025, Gensco Pharma announced the acquisition of the global rights and intellectual property for the first and only rizatriptan Oral Dissolvable Film (ODF), which was co-developed under the trade names RizaFilm in the US and both RizaFilm and RizaPort globally.
• In February 2025, Axsome Therapeutics announced that the EMERGE Phase III trial of SYMBRAVO (MoSEIC meloxicam and rizatriptan) in patients experiencing inadequate response to oral CGRP inhibitors met its primary endpoint, with SYMBRAVO demonstrating statistically significantly greater migraine treatment response compared to oral CGRP inhibitors, as measured by the Migraine Treatment Optimization Questionnaire (mTOQ-4).

Non-Postoperative Pain Management Drug Updates

This section focuses on the uptake rate of potential drugs expected to be launched in the market during 2026-2036, which depends on the competitive landscape, safety, and efficacy data along with order of entry. It is important to understand that the key players evaluating their novel therapies in the pivotal and confirmatory trials should remain vigilant when selecting appropriate comparators to stand the greatest chance of a positive opinion from regulatory bodies, leading to approval, smooth launch, and rapid uptake.

Drug Class/Insights into Leading Emerging and Marketed Therapies in Non-Postoperative Pain Management (2022-2036 Forecast)

The postoperative pain management landscape comprises pharmacological therapies, multimodal analgesia approaches, and non-pharmacological interventions, each targeting different aspects of pain control, inflammation, and functional recovery.

• Pharmacological therapies: Management of non-postoperative pain relies on agents such as NSAIDs, acetaminophen, opioids (for higher-intensity pain), topical formulations, anticonvulsants, ketamine, and local anesthetics. These medications act on different pain pathways, including inflammatory, nociceptive, and neuropathic mechanisms, and are selected based on the underlying cause and severity of pain.
• Multimodal analgesia (MMA): Pain control is optimized by combining multiple pharmacological classes with supportive non-drug strategies such as cold therapy, compression, elevation, immobilization, physiotherapy, and complementary approaches like yoga or massage. This layered approach enhances analgesic response while reducing dependence on opioids and limiting treatment-related adverse effects.
• Mechanism-based anti-inflammatory control: A key therapeutic strategy involves modulation of prostaglandin-mediated inflammation through agents that inhibit cyclooxygenase pathways. NSAIDs reduce prostaglandin synthesis to alleviate pain and inflammation, while selective formulations aim to improve tolerability. When combined with other analgesic classes, these agents contribute to broader, pathway-targeted pain control in acute non-surgical conditions.

Pharmacological therapies remain the cornerstone of non-postoperative pain management, while the increasing adoption of multimodal and non-opioid strategies is driving a shift toward more balanced, safer, and pathway-targeted pain control approaches.

Non-Postoperative Pain Management Drug Uptake

This section focuses on the uptake rate of potential drugs expected to be launched in the market during the forecast period (2026-2036). The analysis covers the postoperative pain management drug's uptake, performance at peak, factors affecting performance during prime years of growth, patient uptake by therapy, and anticipated sales generated by each drug.

The uptake of non-postoperative pain management therapies is expected to vary based on pain type (acute vs chronic), severity, route of administration, and opioid-sparing requirements. NSAIDs and acetaminophen are expected to maintain the highest and most consistent uptake due to their broad use in mild-to-moderate pain and favorable safety profile. In contrast, opioids are expected to see limited and selective use, primarily reserved for moderate-to-severe acute pain, driven by safety concerns and regulatory restrictions.

Adjunct therapies such as ketamine, anticonvulsants, and topical agents are projected to witness moderate but growing adoption, supported by the shift toward multimodal analgesia (MMA). In parallel, non-pharmacological approaches including physical therapy, cold application, and rehabilitation strategies are expected to gain steady traction, particularly in musculoskeletal and injury-related pain, reinforcing a broader move toward integrated pain management.

Detailed insights of emerging therapies' drug uptake is included in the report

Market Access and Reimbursement of Approved therapies in Non-Postoperative Pain Management

The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc. Reimbursement is a crucial factor that affects the drug's access to the market. Often, the decision to reimburse comes down to the price of the drug relative to the benefit it produces in treated patients. To reduce the healthcare burden of these high-cost therapies, many payment models are being considered by payers and other industry insiders.

NOTE: Further Details are provided in the final report....

Non-Postoperative Pain Management Therapies Price Scenario & Trends

Pricing and analogue assessment of postoperative pain management therapies highlights evolving price dynamics structures. This section summarizes the cost of approved treatments, closest and most appropriate analogue selection for emerging therapies, and understanding of how pricing influences market access, adherence, and long-term uptake.

Industry Experts and Physician Views for Non-Postoperative Pain Management

To keep up with Non-Postoperative Pain Management market trends, we take Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs) opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry experts were contacted for insights on the postoperative pain management emerging therapies, evolving treatment landscape, patient adherence to conventional therapies, therapy switching trends, drug adoption and uptake, accessibility challenges, and epidemiology and real-world prescription patterns in postoperative pain management, including MD, PhD, Instructor, Postdoctoral Researcher, Professor, Researcher, and others.

DelveInsight's analysts connected with 15+ KOLs to gather insights at country level. Centers such as the University of Iowa, Stanford University School of Medicine, and McGovern Medical School etc. were contacted.Their opinion helps understand and validate current and emerging postoperative pain management therapies, highlight unmet medical needs, provide epidemiological context, and support strategic decisions for market access, therapy adoption, and pipeline prioritization in postoperative pain management.

Qualitative Analysis: SWOT and Conjoint Analysis

We perform qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and conjoint analysis.

In the SWOT analysis of Non-Postoperative Pain Management, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided.

Conjoint analysis analyzes emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

The team of analysts analyzes promising emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. In efficacy, the trial's primary and secondary outcome measures are evaluated, whereas the therapies' safety is evaluated, wherein the acceptability, tolerability, and adverse events are majorly observed. In addition, the scoring is also based on the route of administration, order of entry, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Scope of the Report:

• The report covers a segment of key events, an executive summary, a descriptive overview of Non-Postoperative Pain Management, explaining their causes, signs and symptoms, pathogenesis, and currently available treatments.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression along treatment guidelines.
• Additionally, an all-inclusive account of both the current and emerging treatments, along with the elaborative profiles of late-stage and prominent therapies, will have an impact on the current treatment landscape.
• A detailed review of the Non-Postoperative Pain Management market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies by understanding trends through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help in shaping and driving the 7MM Non-Postoperative Pain Management market.

Report Insights

• Non-Postoperative Pain Management Patient Population Forecast
• Non-Postoperative Pain Management Therapeutics Market Size
• Non-Postoperative Pain Management Pipeline Analysis
• Non-Postoperative Pain Management Market Size and Trends
• Non-Postoperative Pain Management Market Opportunity (Current and forecasted)

Report Key Strengths

• Epidemiology-based (Epi-based) Bottom-up Forecasting
• Artificial Intelligence (AI)-Enabled Market Research Report
• 11-Year Forecast
• Non-Postoperative Pain Management Market Outlook (North America, Europe, Asia-Pacific)
• Patient Burden Trends (By Geography)
• Non-Postoperative Pain Management Treatment Addressable Market (TAM)
• Non-Postoperative Pain Management Competitive Landscape
• Non-Postoperative Pain Management Major Companies Insights
• Non-Postoperative Pain Management Price Trends and Analogue Assessment
• Non-Postoperative Pain Management Therapies Drug Adoption/Uptake
• Non-Postoperative Pain Management Therapies Peak Patient Share Analysis

Report Assessment

• Non-Postoperative Pain Management Current Treatment Practices
• Non-Postoperative Pain Management Unmet Needs
• Non-Postoperative Pain Management Clinical Development Analysis
• Non-Postoperative Pain Management Emerging Drugs Product Profiles
• Non-Postoperative Pain Management Market attractiveness
• Non-Postoperative Pain Management Qualitative Analysis (SWOT and conjoint analysis)

FAQs:

Market Insights

• What was the postoperative pain management market size, the market size by therapies, market share (%) distribution in 2025, and what would it look like by 2036? What are the contributing factors for this growth?
• What are the anticipated pricing variations among different geographies for the emerging therapies in the future?
• What can be the future treatment paradigm of postoperative pain management?
• What are the disease risks, burdens, and unmet needs of postoperative pain management ? What will be the growth opportunities across the 7MM concerning the patient population with postoperative pain management?
• Who is the major future competitor in the market, and how will the competitors affect their market share?
• What are the current options for the treatment of postoperative pain management? What are the current guidelines for treating postoperative pain management in the US, Europe, and Japan?

Reasons to Buy:

• The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the postoperative pain management market.
• Bottom up forecasting builds from the affected population to product forecasts, delivering a robust, data driven approach ideal for new therapies and novel classes.
• Insights on patient burden/disease incidence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
• Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
• To understand KOLs' perspectives on the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.
• This Artificial Intelligence (AI) enabled report summarize and simplify complex datasets with in the report into clear, actionable insights for stakeholders, investors, and healthcare providers, enabling faster, data driven decisions.

Table of Contents

1. Key Insights

2. Report Introduction

3. Executive Summary

4. Key Events

• 4.1. Key Conferences And Meetings
• 4.2. Key Transactions And Collaborations
• 4.3. News Flow

5. Epidemiology and Market Forecast Methodology

6. Non-Postoperative Pain Management Market Overview at a Glance

• 6.1. Clinical Landscape Analysis (By Molecule Type, Phase, and Route of Administration [ROA])
• 6.2. Market Share (%) Distribution of Non-Postoperative Pain Management by Therapy in 2025
• 6.3. Market Share (%) Distribution of Non-Postoperative Pain Management by Therapy in 2036

7. Disease Background and Overview

• 7.1. Introduction
• 7.2. Difference between Acute and Chronic Pain
• 7.3. The Transition of Acute pain to Chronic Pain
• 7.4. Types of Acute Pain
• 7.5. Signs and Symptoms
• 7.6. Causes
• 7.7. Pathophysiology of Acute Pain
  • 7.7.1. Effects on Key Target Organs
• 7.8. Diagnosis
  • 7.8.1. Pain Scales used for Assessment of Pain
  • 7.8.2. Diagnostic Algorithm
• 7.9. Treatment
  • 7.9.1. Non-pharmacological Treatments for Non-Postoperative Pain Management
  • 7.9.2. Pharmacological Treatments of Non-Postoperative Pain Management

8. Treatment Guidelines

• 8.1. CDC Clinical Practice Guideline for Prescribing Opioids for Pain-United States
• 8.2. Non-Postoperative Pain Management in Nontraumatic Emergency General Surgery: WSES-GAIS-SIAARTI-AAST Guidelines
• 8.3. American Academy of Family Physicians: Pharmacologic Therapy for Acute Pain
• 8.4. Recent Advances in Acute Pain Management: Understanding the Mechanisms of Acute Pain, the Prescription of Opioids, and the Role of Multimodal Pain Therapy
• 8.5. Management of Non-Postoperative Pain: A Clinical Practice Guideline From the American Pain Society, the Management of Non-Postoperative Pain: A Clinical Practice Guideline From the American Pain Society, the American Society of Regional Anesthesia and Pain Medicine, and the American Society of Anesthesiologists Committee on Regional Anesthesia, Executive Committee, and Administrative Council (2017)

9. Epidemiology and Patient Population

• 9.1. Key Findings
• 9.2. Assumptions and Rationale: 7MM
• 9.3. Epidemiology in the United States
  • 9.3.1. Total Incident Cases of Non-Postoperative Pain in the United States (2022-2036)
  • 9.3.2. Severity-specific Incident Cases of Non-Postoperative Pain in the United States (2022-2036)
  • 9.3.3. Total Treated Pool of Non-Postoperative Pain in the United States (2022-2036)
• 9.4. Epidemiology in EU4 and the UK
  • 9.4.1. Total Incident Cases of Non-Postoperative Pain in EU4 and the UK (2022-2036)
  • 9.4.2. Severity-specific Incident Cases of Non-Postoperative Pain in EU4 and the UK (2022-2036)
  • 9.4.3. Total Treated Pool of Non-Postoperative Pain in EU4 and the UK (2022-2036)
• 9.5. Epidemiology Scenario in Japan
  • 9.5.1. Total Incident Cases of Non-Postoperative Pain (2022-2036)
  • 9.5.2. Severity-specific Incident Cases of Non-Postoperative Pain in Japan (2022-2036)
  • 9.5.3. Total Treated Pool of Non-Postoperative Pain in Japan (2022-2036)

10. Patient Journey of Non-Postoperative pain

11. Marketed Therapies

• 11.1. Competitive Landscape: Marketed Therapies
• 11.2. dihydroergotamine mesylate (ATZUMI): Satsuma Pharmaceuticals
  • 11.2.1. Product Description
  • 11.2.2. Regulatory Milestones
  • 11.2.3. Other Developmental Activities
  • 11.2.4. Summary of Pivotal Trials
  • 11.2.5. Analyst's View
• 11.3. galcanezumab-gnlm (EMGALITY): Eli Lily
  • 11.3.1. Product Description
  • 11.3.2. Regulatory Milestones
  • 11.3.3. Other Developmental Activities
  • 11.3.4. Summary of Pivotal Trials
  • 11.3.5. Analyst's View
• 11.4. zavegepant (ZAVZPRET): Pfizer
  • 11.4.1. Product Description
  • 11.4.2. Regulatory Milestones
  • 11.4.3. Other Developmental Activities
  • 11.4.4. Summary of Pivotal Trials
  • 11.4.5. Analyst's View
• 11.5. rimegepant (NURTEC ODT/VYDURA): Pfizer
  • 11.5.1. Product Description
  • 11.5.2. Regulatory Milestones
  • 11.5.3. Other Developmental Activities
  • 11.5.4. Summary of Pivotal Trials
  • 11.5.5. Analyst's View
• 11.6. dihydroergotamine mesylate (TRUDHESA): Impel Pharmaceuticals
  • 11.6.1. Product Description
  • 11.6.2. Regulatory Milestones
  • 11.6.3. Other Developmental Activities
  • 11.6.4. Summary of Pivotal Trials
  • 11.6.5. Analyst's View
• 11.7. DEXTENZA (dexamethasone): Ocular Therapeutix
  • 11.7.1. Product Description
  • 11.7.2. Regulatory Milestones
  • 11.7.3. Other Developmental Activities
  • 11.7.4. Summary of Pivotal Trials
  • 11.7.5. Analyst's View
• 11.8. lasmiditan (REYVOW/RAYVOW): Eli Lilly
  • 11.8.1. Product Description
  • 11.8.2. Regulatory Milestones
  • 11.8.3. Other Developmental Activities
  • 11.8.4. Summary of Pivotal Trials
  • 11.8.5. Analyst's View
• 11.9. celecoxib (ELYXYB): Scilex Holding
  • 11.9.1. Product Description
  • 11.9.2. Regulatory Milestones
  • 11.9.3. Other Developmental Activities
  • 11.9.4. Summary of Pivotal Trials
  • 11.9.5. Analyst's View

12. Emerging Drugs

• 12.1. Competitive Landscape: Emerging Therapies
• 12.2. esflurbiprofen transdermal (TK-254Rx): Cali Biosciences
  • 12.2.1. Product Description
  • 12.2.2. Other Development Activities
  • 12.2.3. Clinical Development
    • 12.2.3.1. Clinical Trial Information
  • 12.2.4. Safety and Efficacy
  • 12.2.5. Analyst's View
• 12.3. rizatriptan (RizaFilm): Gensco Pharma
  • 12.3.1. Product Description
  • 12.3.2. Other Development Activities
  • 12.3.3. Clinical Development
    • 12.3.3.1. Clinical Trial Information
  • 12.3.4. Safety and Efficacy
  • 12.3.5. Analyst View
• 12.4. ELYXYB: Scilex Holding Company
  • 12.4.1. Product Description
  • 12.4.2. Other Development Activities
  • 12.4.3. Clinical Development
    • 12.4.3.1. Clinical Trial Information
  • 12.4.4. Safety and Efficacy
  • 12.4.5. Analyst's View
• 12.5. CT001: Cessatech A/S
  • 12.5.1. Product Description
  • 12.5.2. Other Development Activities
  • 12.5.3. Clinical Development
    • 12.5.3.1. Clinical Trial Information
  • 12.5.4. Safety and Efficacy
  • 12.5.5. Analyst's View

13. Non-Postoperative Pain Management: 7MM Analysis

• 13.1. Key Findings
• 13.2. Market Outlook
• 13.3. Conjoint Analysis
• 13.4. Key Market Forecast Assumptions
  • 13.4.1. Cost Assumptions and Rebates
  • 13.4.2. Pricing Trends
  • 13.4.3. Analogue Assessment
  • 13.4.4. Launch Year and Therapy Uptakes
• 13.5. Total Market Size of Non-Postoperative Pain Management in the 7MM
• 13.6. The United States
  • 13.6.1. Total Market Size of Non-Postoperative Pain Management in the United States
  • 13.6.2. Total Market Size of Non-Postoperative Pain Management by Therapies in the United States
• 13.7. EU4 and the UK
  • 13.7.1. Total Market Size of Non-Postoperative Pain Management in EU4 and the UK
  • 13.7.2. Total Market Size of Non-Postoperative Pain Management by Therapies in EU4 and the UK
• 13.8. Japan
  • 13.8.1. Total Market Size of Non-Postoperative Pain Management in Japan
  • 13.8.2. Total Market Size of Non-Postoperative Pain Management by Therapies in Japan

14. Unmet Needs of Non-Postoperative Pain Management

15. SWOT Analysis of Non-Postoperative Pain Management

16. KOL Views of Non-Postoperative Pain Management

17. Market Access and Reimbursement of Non-Postoperative Pain Management

18. Appendix

• 18.1. Bibliography
• 18.2. Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight